Get the Stockscreener App
25.45
0.43%
-0.11
After Hours:
25.45
Xoma Corporation stock is traded at $25.45, with a volume of 2,268.
It is down -0.43% in the last 24 hours and up +0.20% over the past month.
XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
See More
Previous Close:
$25.56
Open:
$25.4
24h Volume:
2,268
Relative Volume:
0.36
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-0.16%
1M Performance:
+0.20%
6M Performance:
+0.43%
1Y Performance:
-0.59%
1-Day Range:
$25.40
$25.59
1-Week Range:
$25.00
$25.63
52-Week Range:
$23.32
$25.76
Xoma Corporation Stock (XOMAO) Company Profile
Name
Xoma Corporation
Sector
Industry
Phone
510 204 7200
Address
2200 Powell Street, Suite 310, EmeryVille
Compare XOMAO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XOMAO
Xoma Corporation
|
25.45 | 0 | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.38 | 114.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
748.71 | 78.80B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
396.04 | 51.80B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
847.05 | 53.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
166.55 | 42.33B | 447.02M | -1.18B | -906.14M | -6.1812 |
Xoma Corporation Stock (XOMAO) Latest News
Can XOMA Royalty Corporation stock double in next 5 yearsWeekly Trade Review & Free Risk Controlled Daily Trade Plans - Улправда
Jefferies downgrades Generation Bio stock to Hold as XOMA acquisition announced By Investing.com - Investing.com South Africa
Generation Bio is latest Mass. biotech to be acquired by Xoma - The Business Journals
XOMA to buy struggling Generation Bio - The Pharma Letter
Jefferies downgrades Generation Bio stock to Hold as XOMA acquisition announced - Investing.com Nigeria
‘Zombie’ biotech buyer Xoma to acquire Generation Bio - Yahoo Finance
XOMA Strikes Deal To Acquire Generation Bio, Expanding Royalty Portfolio - Nasdaq
XOMA Royalty to Acquire Generation Bio - citybiz
Generation Bio Announces Merger with XOMA Royalty - TipRanks
Xoma Royalty enters into agreement to acquire Generation Bio - marketscreener.com
XOMA Royalty Corporation to Acquire Generation Bio Co. in Cash Transaction with Milestone and Royalty Opportunities - Quiver Quantitative
Generation Bio (NASDAQ: GBIO) agrees to $4.29 sale to XOMA Royalty plus CVR - Stock Titan
Investors Don't See Light At End Of XOMA Royalty Corporation's (NASDAQ:XOMA) Tunnel - simplywall.st
Generation Bio (GBIO) to be acquired in planned XOMA tender offer - Stock Titan
FY2025 EPS Estimates for XOMA Royalty Reduced by Analyst - MarketBeat
XOMA Royalty Corporation: A Deep Dive into a Biotech Royalty Aggregator (12/13/2025) - Markets Financial Content
BVF Inc. IL Has $65.28 Million Stock Position in XOMA Royalty Corporation $XOMA - MarketBeat
Why (XOMAO) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
Price-Driven Insight from (XOMA) for Rule-Based Strategy - news.stocktradersdaily.com
XOMA stock maintains Buy rating at Benchmark despite partner’s trial setback - Investing.com
XOMA: HC Wainwright Maintains Buy Rating, Lowers Price Target to $97 | XOMA Stock News - GuruFocus
Leerink Partners lowers XOMA stock price target on RZ358 trial failure By Investing.com - Investing.com South Africa
HC Wainwright & Co. Maintains XOMA Royalty (XOMA) Buy Recommendation - Nasdaq
HC Wainwright & Co. Maintains XOMA Royalty CorporationPreferred Stock (XOMAP) Buy Recommendation - Nasdaq
Why two Bay Area companies' stocks tumbled on a drug's clinical failure - The Business Journals
XOMA stock price target lowered to $97 by H.C. Wainwright - Investing.com Australia
XOMA Royalty Corporation (NASDAQ:XOMA) Receives Average Rating of "Hold" from Brokerages - MarketBeat
XOMA: Leerink Partners Lowers Price Target, Reiterates Outperfor - GuruFocus
Why Is XOMA Royalty Stock Sinking Thursday? - Benzinga
Leerink Partners lowers XOMA stock price target on RZ358 trial failure - Investing.com
LUCID CAPITAL MARKETS Initiates Coverage of XOMA Royalty CorporationPreferred Stock (XOMAP) with Buy Recommendation - Nasdaq
LUCID CAPITAL MARKETS Initiates Coverage of XOMA Royalty (XOMA) with Buy Recommendation - Nasdaq
Lucid Capital Markets initiates coverage on XOMA stock with Buy rating - Investing.com Canada
XOMA Royalty (XOMA): New Buy Rating Initiated by Lucid Capital M - GuruFocus
Xoma initiated with a Buy at Lucid Capital - TipRanks
CEO’s Bold Move: Massive Investment in Xoma Stock! - TipRanks
Insider Buying: XOMA Royalty (NASDAQ:XOMA) CEO Acquires 100,000 Shares of Stock - MarketBeat
XOMA Royalty Corp CEO Owen Hughes Acquires 100,000 Depositary Shares - TradingView
Xoma Royalty Expands Portfolio Through Mural Oncology Acquisition - AD HOC NEWS
XOMA Royalty completes acquisition of Mural Oncology for $2.035 per share - Investing.com Nigeria
XOMA Royalty completes acquisition of Mural Oncology By Investing.com - Investing.com Nigeria
Xoma Completes Acquisition of Mural Oncology - TipRanks
Xoma announces closing of transaction to acquire Mural Oncology - TipRanks
XOMA Royalty completes acquisition of Mural Oncology for $2.035 per share By Investing.com - Investing.com South Africa
Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition - Research Tree
Xoma Royalty announces closing of transaction to acquire Mural Oncology plc - marketscreener.com
XOMA Royalty Corporation Completes Acquisition of Mural Oncology plc Under Irish High Court Sanctioned Scheme - Quiver Quantitative
XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc - The Manila Times
XOMA Royalty (Nasdaq: XOMA) completes $2.035 per share Mural Oncology takeover - Stock Titan
XOMA Royalty completes acquisition of Mural Oncology - Investing.com India
Mural Oncology plc Announces Effective Date of Scheme Arrangement for Acquisition by XOMA Royalty Corporation - Quiver Quantitative
Xoma Corporation Stock (XOMAO) Financials Data
There is no financial data for Xoma Corporation (XOMAO). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.31%
0.33%
Cap:
|
Volume (24h):